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The etiology of PVOD remains unclear. It has been reported as an unusual complication of both myeloablative allogeneic and autologous transplantation, suggesting that it might be a regimen-related toxicity. [2] [3] [4] [5] [6] Anecdotally, PVOD has also been reported following routine cytoreductive chemotherapy. Bleomycin, mitomycin and carmustine (BCNU) have been particularly implicated as potential etiologic agents. 7 In addition, infection and autoimmune disorders have been suggested as potential causes of PVOD, but there are scant data to confirm these associations. 8, 9 We report a case of PVOD following reduced-intensity cord blood transplantation (CBT).
A 51-year-old woman was hospitalized for progressive dyspnea on exertion and hypoxia 80 days following a second reduced-intensity double unit CBT. Five months before, the patient underwent the first reduced-intensity double unit CBT for high-risk AML in first CR. Conditioning was 200 mg/m 2 fludarabine, 50 mg/kg CY, 2 Gy TBI) and 90 mg antithymocyte globulin. GVHD prophylaxis was CYA and mycophenolate mofetil. Although the patient engrafted neutrophils on day 6, she subsequently developed graft failure with marginal autologous hematopoietic recovery by day 50. Three months after her initial CBT, the patient underwent salvage, second reduced-intensity CBT following conditioning with 200 mg/m 2 fludarabine, 50 mg/kg CY and 4 Gy TBI. GVHD prophylaxis was CY and mycophenolate mofetil. The patient engrafted neutrophils on day 25 and developed 100 percent single donor chimerism by day 28. Computed tomography (CT) of the chest before the second CBT demonstrated only sub 5 mm pulmonary nodules, stable compared to prior imaging, and echocardiogram revealed normal left and right ventricular function without evidence of pulmonary hypertension (estimated pulmonary artery (PA) systolic pressure 19.4 mm Hg). Her post-transplantation course was notable only for intermittently positive reactivation of CMV by PCR treated with foscarnet and ganciclovir, and spontaneously resolved cystitis associated with BK virus viruria.
Two months after her second CBT, the patient was admitted with cough, wheezing, dyspnea and room air arterial oxygen saturation of 88 percent. The chest CT showed septal thickening, small bilateral pleural effusions, scattered multifocal ground glass opacities and patchy left lower lobe airspace opacities ( Figure 1 ). Bronchoscopy was negative for infections. In spite of improvement in the airspace disease on levofloxacin and furosemide, dyspnea and hypoxia persisted and the pleural effusions enlarged. The patient was readmitted 80 days following the second CBT, at which point CT angiography revealed no evidence of pulmonary embolus, and inferior vena cava and bilateral lower extremity dopplers revealed no evidence of deep venous thrombosis. Echocardiogram revealed moderate PA hypertension (estimated PA systolic pressure 56.2 mm Hg) with normal left ventricular size and function. Pulmonary function tests demonstrated forced vital capacity (FVC) 1.61 l (42% predicted), forced expiratory volume (FEV1) 1.4 l (46% predicted), and corrected diffusing capacity of the lung for carbon monoxide (DLCO) 5.2 ml/mm Hg/min (18% predicted; baseline pre-transplantation values FVC 3.45 l (91% predicted), FEV1 2.85 l (94% predicted), corrected DLCO 20.3 ml/mm Hg/min (71% predicted)). Right heart catheterization demonstrated moderate PA hypertension (PA systolic pressure 48 mm Hg, PA diastolic pressure 15 mm Hg, mean PA pressure 29 mm Hg) with normal pulmonary capillary wedge pressure (4 mm Hg). Lung biopsy by thorascopic wedge resection showed PVOD affecting small venules and tiny parenchymal vessels primarily (Figure 2 ) as well as mild hemosiderin deposition in intra-alveolar septa. Autoimmune and vasculitis testing, including antinuclear antibody (ANA), anti-SCL 70, C and P anti-neutrophil cytoplasmic antibody (ANCAs) were negative.
The patient was placed on therapeutic unfractionated heparin followed by warfarin and prednisone at 1 mg/kg orally per day. Eight months after the diagnosis of PVOD, the patient's pulmonary symptoms have largely resolved. Prednisone has been tapered to 5 mg orally per day and the patient is maintained on warfarin. The chest CT demonstrates resolution of pleural effusions and septal thickening. FVC has improved to 3.74 l (66% predicted), FEV1 has improved to 2.84 l (77% predicted) and DLCO remains stable. Echocardiogram reveals normal right ventricular function without evidence of PA hypertension.
To our knowledge, we are the first to report a case of PVOD following the reduced-intensity conditioning and the first to report PVOD following CBT. Though PVOD is a rare reported complication of myeloablative SCT, it has been presumed to be a regimen-related toxicity. Our patient had undergone two CBT, but both were reduced intensity. Infection has also been suggested as a possible cause of PVOD, and though our patient did not exhibit an obvious infection, CBT patients are particularly immunocompromised following transplantation. The possibility of occult viral infection contributing to the condition must be considered. Finally, autoimmunity has also been suggested as a contributing factor associated with PVOD, and although our patient experienced no significant GVHD, the possibility exists of donor/host interactions contributing to the condition.
The diagnosis of PVOD requires a high index of suspicion. Patients typically present with dyspnea on exertion and fatigue. CT scans may reveal smooth septal thickening, diffuse or mosaic ground glass opacities, pleural effusions or areas of alveolar consolidation. Cardiac catheterization reveals normal or decreased PA wedge pressure with elevated pulmonary capillary pressures. Surgical lung biopsy provides definitive diagnosis. 9 Treatment recommendations for PVOD are anecdotal. Owing to the rarity of the condition, its natural history is not well defined, and milder and nonfatal forms with spontaneous resolution of pulmonary venular obstruction may be an under-recognized course of the disease. Our patient did demonstrate evidence of some recanalization of pulmonary vasculature on biopsy, and this finding may portend a more favorable prognosis. Steroids and heparin have been reported to possibly improve outcomes, 3 and our patient appears to have had stabilization and improvement of disease on these agents. Defibrotide and N-acetylcysteine hold appeal as potential therapeutic agents, but no data have been reported regarding their efficacy. The role of PA dilators in treating PVOD is controversial. Although sildenafil, prostacyclins and calcium channel blockers have been reported to improve the symptoms in isolated case reports, use of these agents warrants significant caution given the fixed venular obstruction in PVOD. Dilation of the PA tree in this setting may lead to profound pulmonary edema. 9 Pulmonary veno-occlusive disease should be included in the differential diagnosis of dyspnea and hypoxia following reduced-intensity transplantation and CBT. Additional case reports describing the condition may yield further insights into its etiology. 
